Abstract
Liver biopsy is an invasive diagnostic method for detecting liver involvement (LI) in Hodgkin's disease (HD). The aim of this retrospective study was to determine and evaluate a method for restricting liver biopsy to a subset of patients. Between 1988 and 1994, a total of 2016 patients with HD were treated within the HD4–6 study protocol of the German Hodgkin's Lymphoma Study Group (GHSG). We investigated the predictive power of abdominal ultrasound (US) and computed tomography (CT), as well as of various clinical factors related to LI, using univariate and multivariate methods. LI occurred in 4.9% of all patients (99/2016) and in 3.0% of those who, if LI were disregarded, would have been included in clinical stages I and II. In multivariate analysis the presence of LI was significantly associated with splenic involvement or infradiaphragmatic involvement, absence of mediastinal involvement, serum alkaline phosphatase (SAP) level over 230 units/l, and age over 40 years. We used these factors to define a risk score for LI. LI is very rare in patients who would otherwise be in clinical stages I or II, but knowledge of LI is important because it has therapeutic consequences. With our risk score, liver biopsy is indicated for approximately one quarter of these patients otherwise in clinical stages I or II.
Similar content being viewed by others
Author information
Authors and Affiliations
Consortia
Additional information
Received: April 26, 1999 / Accepted: July 9, 1999
Rights and permissions
About this article
Cite this article
Lieberz, D., Sextro, M., Paulus, U. et al. How to restrict liver biopsy to high-risk patients in early-stage Hodgkin's disease. Ann Hematol 79, 73–78 (2000). https://doi.org/10.1007/s002770050013
Issue Date:
DOI: https://doi.org/10.1007/s002770050013